Comparison of the drugs used for cardioversion of paroxysmal supra - ventricular tachycardia in children: 40 cases
- VernacularTitle:40例小儿阵发性室上性心动过速静脉药物复律比较研究
- Author:
Jiarong ZHONG
- Publication Type:Journal Article
- Keywords:
Paroxysmal supra - ventricular tachycardia;
Cardioversion;
children
- From:
Journal of Chongqing Medical University
2003;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective;To compare and assess the curative effects, starting time and side effects of cardioversion drugs used for treatment of paroxysmal supra - ventricular tachycardia ( PSVT) , including adenosine triphosphate ( ATP) , dofetilide, and cedilanid. Methods; The data of 40 admitted children with PSVT treated with ATP, dofetilide and cedilanid in recent 5 years were collected. The cardioversion time, success rate and side effects of the drugs were compared. The constituent ratio was determined with check x2. Significant level a was 0.05. Results: In group ATP, 89.47% of patients were interrupted; 63. 15% of them had side effects; the cardioversion time of ATP was 3-30 seconds. In group dofetilide, 72.73% the patients were interrupted; 9.09% of them had side effects; the cardioversion time of dofetilide was 5- 30min. In group cedilanid, 61. 11% the patients were interrupted; 5. 55% of them had side effects; the cardioversion time of dofetilide was 20min -5h. Conclusion; ATP should be considered the drug of first choice for PSVT in children without organic heart diseases and serious complication and it has only minor and transient side effects. Dofetilide is equally effective in interrupting PSVT, and has minor side effects, which should be considered the first choice and best suitable for atrioventric-ular reentrant tachycardia. Cedilanid should be considered the drug of first choice for PSVT in children with serious heart failure, and it has a synergic effect to ATP and dofetilide.
